Current treatments

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Bahlis NJ et al. Leukemia. 2017 Apr 4. doi: 10.1038/leu.2017.111. [Epub ahead of print]. Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma. Knop S et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.124. [Epub ahead of print]. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation…

Details

Study highlights challenges associated with early diagnosis of myeloma and other cancers

A study examining the number of visits people made to their GP before being diagnosed with cancer through accident and emergency (A&E) has shown that myeloma patients presenting via this route have the highest number of prior GP visits than any other cancer. Published recently in the British Journal Of General Practice, researchers from the Universities of…

Details

IMWG Consensus statement on the role of 18F-FDG PET/CT in the diagnosis and management of myeloma and related diseases

This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of  18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.

Read article

Diagnostic tests and prognostic indicators

Diagnostic accuracy of computed tomography-guided biopsy in pathological fractures. Stokes CM et al. ANZ J Surg. 2017 Mar 17. doi: 10.1111/ans.13894. [Epub ahead of print]. Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Dutoit JC et al. Skeletal Radiol. 2017 Mar 13. doi: 10.1007/s00256-017-2609-6. [Epub ahead of print]. CXCR4 (CD184) expression on stem cell harvest and…

Details

Related conditions

POEMS Syndrome: an Enigma. Warsame R et al. Curr Hematol Malig Rep. 2017 Mar 15. doi: 10.1007/s11899-017-0367-0. [Epub ahead of print]. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept. Ramirez-Alvarado M et al. Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24717. [Epub ahead of print]. The risk of renal disease is increased in…

Details

Emerging treatments

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Shah N et al. Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14570. [Epub ahead of print]. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Sborov DW et al. Leuk Lymphoma. 2017 Mar 7:1-9. doi: 10.1080/10428194.2017.1298751.…

Details

Biology and genetics

p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Tessoulin B et al. Blood Rev. 2017 Mar 4. pii: S0268-960X(16)30059-5. doi: 10.1016/j.blre.2017.03.001. [Epub ahead of print]. Mesenchymal stromal cells enhance the suppressive effects ofmyeloid-derived suppressor cells of multiple myeloma. Xu Y et al. Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1298753. [Epub ahead of print]. Identification of…

Details

General

Update on the optimal use of bortezomib in the treatment of multiple myeloma. Mohan M et al. Cancer Manag Res. 2017 Mar 2;9:51-63. doi: 10.2147/CMAR.S105163. eCollection 2017. Multiple Myeloma: Diagnosis and Treatment. Michels TC et al. Am Fam Physician. 2017 Mar 15;95(6):373-383. Monoclonal antibody therapy in multiple myeloma. Touzeau C et al. Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.60. [Epub ahead of print]. Patients with myeloma need more time…

Details

Supportive treatments

Reinforced cementoplasty using dedicated spindles in the management of unstable malignant lesions of the cervicotrochanteric region. Premat K et al. Eur Radiol. 2017 Mar 13. doi: 10.1007/s00330-017-4774-3. [Epub ahead of print]. Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study. Losem C et al. Onco Targets Ther. 2017 Feb…

Details